VBL Therapeutics to Participate at Upcoming Virtual Investor Conferences

Rhea-AI Summary

VBL Therapeutics (Nasdaq: VBLT) announced its participation in three upcoming virtual investor conferences:

• H.C Wainwright Global Life Sciences Conference on March 9, 2021, with on-demand presentations starting at 7:00 a.m. ET.
• 33rd Annual Roth Conference on March 15, 2021, featuring a panel on cancer at 10:00 a.m. ET.
• 31st Annual Oppenheimer Healthcare Conference on March 16, 2021, with a fireside chat at 8:00 a.m. ET.

Webcasts are accessible on the Company’s Investor Relations page.

TEL AVIV, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences:

H.C Wainwright Global Life Sciences Conference
Tuesday, March 9, 2021
Presentation available on-demand beginning at 7:00 a.m. ET

33rd Annual Roth Conference
Date: Monday, March 15, 2021
Panel discussion time: 10:00 a.m. ET
Title: Cancer – Heterogeneous Approaches to a Heterogeneous Etiology

31st Annual Oppenheimer Healthcare Conference
Date: Tuesday, March 16, 2021
Fireside chat time: 8:00 a.m. ET

Webcasts will be available via the Events and Presentations section of the Company’s Investor Relations page.

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements may include, but are not limited to, statements regarding our programs, including VB-111, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, that our financial resources do not last for as long as anticipated, and that we may not realize the expected benefits of our intellectual property protection. In particular, the DSMC recommendation that the OVAL trial proceed is not assurance that the trial will meet its primary endpoint of overall survival once completed, or that we will obtain positive results to support further development of this candidate.  A further list and description of these risks, uncertainties and other risks can be found in our regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2019, and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. 

CONTACT:
Burns McClellan for VBL Therapeutics
Lee Roth (investors) / Ryo Imai (media)
lroth@burnsmc.com / rimai@burnsmc.com
+1-212-213-0006

FAQ

What investor conferences will VBL Therapeutics participate in March 2021?

VBL Therapeutics will participate in the H.C Wainwright Global Life Sciences Conference on March 9, the 33rd Annual Roth Conference on March 15, and the 31st Annual Oppenheimer Healthcare Conference on March 16, 2021.

When will the H.C Wainwright Global Life Sciences Conference presentation be available?

The presentation for the H.C Wainwright Global Life Sciences Conference will be available on-demand starting at 7:00 a.m. ET on March 9, 2021.

What is the topic of the panel discussion at the 33rd Annual Roth Conference?

The panel discussion at the 33rd Annual Roth Conference is titled 'Cancer – Heterogeneous Approaches to a Heterogeneous Etiology' and will take place at 10:00 a.m. ET on March 15, 2021.

What time is VBL Therapeutics' fireside chat at the Oppenheimer Healthcare Conference?

VBL Therapeutics' fireside chat at the 31st Annual Oppenheimer Healthcare Conference is scheduled for 8:00 a.m. ET on March 16, 2021.

Where can I watch the webcasts for VBL Therapeutics' conference presentations?

The webcasts for VBL Therapeutics' conference presentations can be accessed via the Company’s Investor Relations page.